The options paper acknowledged that the need for multiple submissions could delay funded patient access for several years. Yet it effectively accepted them as an intractable feature of our HTA systems. …
The process does not cause delays, it promotes them for the best medicines
August 5, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Australian company partners to take innovative therapy to Asia
June 17, 2026 - - Latest News -
Novartis names interim leader for Australia and NZ after Country President departs
June 17, 2026 - - Latest News -
These outcomes are mostly about the choices Australia is making
June 17, 2026 - - Latest News -
AstraZeneca confirms pricing the issue, and acts to create a patient access program
June 16, 2026 - - Latest News -
When good policy becomes self defeating, Australia must at least have a discussion about the obvious solution
June 16, 2026 - - Latest News -
Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder
June 15, 2026 - - Australian Biotech -
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 - - Australian Biotech